Momelotinib Usage Within Our Current Canadian Myelofibrosis Armamentarium
DOI:
https://doi.org/10.58931/cht.2025.4s0262Abstract
Myelofibrosis (MF) can be categorized as primary MF (PMF), or secondary MF, which comprises post-polycythemia MF (PPV) and post-essential thrombocythemia (PET). Activating mutations in JAK2, CALR, or MPL are the main driver mutations resulting in abnormal signalling that promotes cell proliferation and survival, leading to secretion of inflammatory cytokines causing myeloproliferation, bone marrow fibrosis, and extramedullary hematopoiesis in MF.
The current treatment landscape for MF consists of strategies to reduce spleen volume and improve MF-related symptoms with less effective results in improving cytopenias. Mainstay therapies have included hydroxyurea (HU) and Janus kinase inhibitors (JAKi), as well as curative allogeneic stem cell transplant (ASCT), though fewer patients are eligible for this treatment. Several JAKi have been approved in Canada for first-line treatment, including ruxolitinib, fedratinib, and most recently, momelotinib. Approximately 40% of patients with MF have anemia at diagnosis, and nearly 25% are red blood cell (RBC) transfusion-dependent (TD). Many patients with MF struggle with symptoms related to chronic anemia, and anemia often progresses with time, leading to transfusion dependence for many patients. Anemia of any severity negatively impacts MF survival and is highlighted as a negative prognostic factor among most validated MF scoring systems. Anemia results in increased patient fatigue and lower quality of life (QoL), which results in increased healthcare utilization. Severe anemia results in a 2-fold increased healthcare resource utilization compared to mild anemia. This review focuses on the current treatment approaches for MF, with particular focus on MF-related anemia and the targeted role of newer JAKi, such as momelotinib.
References
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. [cited 2025 Jan 9]; Available from: http://ashpublications.org/blood/article-pdf/140/11/1200/1921032/bloodbld2022015850c.pdf
Vainchenker W, Kralovics R. Review Series Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. 2017 [cited 2025 Jan 9]; Available from: http://ashpublications.org/blood/article-pdf/129/6/667/1401970/blood695940.pdf DOI: https://doi.org/10.1182/blood-2016-10-695940
Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R, et al. One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience. Mayo Clin Proc [Internet]. 2012 [cited 2025 Jan 9];87(1):25. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3538387/ DOI: https://doi.org/10.1016/j.mayocp.2011.11.001
Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood [Internet]. 2010 Mar 4 [cited 2025 Jan 9];115(9):1703–8. Available from: https://dx.doi.org/10.1182/blood-2009-09-245837 DOI: https://doi.org/10.1182/blood-2009-09-245837
Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. Journal of Clinical Oncology [Internet]. 2011 Feb 1 [cited 2025 Jan 9];29(4):392–7. Available from: https://ascopubs.org/doi/10.1200/JCO.2010.32.2446 DOI: https://doi.org/10.1200/JCO.2010.32.2446
Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, et al. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. J Clin Oncol [Internet]. 2018 Feb 1 [cited 2025 Jan 9];36(4):310–8. Available from: https://pubmed.ncbi.nlm.nih.gov/29226763/ DOI: https://doi.org/10.1200/JCO.2017.76.4886
Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, et al. MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. J Clin Oncol [Internet]. 2018 Jun 10 [cited 2025 Jan 9];36(17):1769–70. Available from: https://pubmed.ncbi.nlm.nih.gov/29708808/ DOI: https://doi.org/10.1200/JCO.2018.78.9867
Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia [Internet]. 2017 [cited 2025 Jan 9];31(12):2726–31. Available from: https://pubmed.ncbi.nlm.nih.gov/28561069/ DOI: https://doi.org/10.1038/leu.2017.169
Gerds AJTL. Evaluating estimated health care resource utilization and costs in patients with myelofibrosis based on transfusion status and anemia severity: A retrospective analysis of the Medicare Fee-For-Service claims data affiliations. J Manag Care Spec Pharm . 2024;30(12):1395–404. DOI: https://doi.org/10.18553/jmcp.2024.24050
Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. 2009 [cited 2025 Jan 23]; Available from: http://www.stata.com DOI: https://doi.org/10.1182/blood-2008-07-170449
Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, et al. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw [Internet]. 2022 Sep 1 [cited 2025 Jan 23];20(9):1033–62. Available from: https://pubmed.ncbi.nlm.nih.gov/36075392/ DOI: https://doi.org/10.6004/jnccn.2022.0046
Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: Prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. Journal of Clinical Oncology [Internet]. 2012 Nov 20 [cited 2025 Jan 10];30(33):4098–103. Available from: https://ascopubs.org/doi/10.1200/JCO.2012.42.3863 DOI: https://doi.org/10.1200/JCO.2012.42.3863
Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol [Internet]. 2011 Feb 10 [cited 2025 Jan 10];29(5):573–82. Available from: https://pubmed.ncbi.nlm.nih.gov/21220604/ DOI: https://doi.org/10.1200/JCO.2010.29.8711
Pardanani A, Finke C, Abdelrahman RA, Lasho TL, Tefferi A. Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis. [cited 2025 Jan 10]; Available from: https://onlinelibrary.wiley.com/doi/10.1002/ajh.23406,
McLornan DP, Psaila B, Ewing J, Innes A, Arami S, Brady J, et al. The management of myelofibrosis: A British Society for Haematology Guideline. Br J Haematol. 2024 Jan 1;204(1):136–50. DOI: https://doi.org/10.1111/bjh.19186
Hernández-Boluda JC, Correa JG, García-Delgado R, Martínez-López J, Alvarez-Larrán A, Fox ML, et al. Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis. Eur J Haematol [Internet]. 2017 Apr 1 [cited 2025 Jan 10];98(4):407–14. Available from: https://pubmed.ncbi.nlm.nih.gov/28009442/ DOI: https://doi.org/10.1111/ejh.12846
Cervantes F, Isola IM, Alvarez-Larrán A, Hernández-Boluda JC, Correa JG, Pereira A. Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. Ann Hematol [Internet]. 2015 Nov 22 [cited 2025 Jan 10];94(11):1791–6. Available from: https://pubmed.ncbi.nlm.nih.gov/26122869/ DOI: https://doi.org/10.1007/s00277-015-2435-7
Castillo-Tokumori F, Talati C, Al Ali N, Sallman D, Yun S, Sweet K, et al. Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis. Clin Lymphoma Myeloma Leuk [Internet]. 2020 Dec 1 [cited 2025 Jan 10];20(12):e956–60. Available from: https://pubmed.ncbi.nlm.nih.gov/32778513/ DOI: https://doi.org/10.1016/j.clml.2020.07.006
Fenaux P, Kiladjian JJ, Platzbecker U. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. 2019 [cited 2025 Jan 23]; Available from: http://ashpublications.org/blood/article-pdf/133/8/790/1557740/blood876888.pdf DOI: https://doi.org/10.1182/blood-2018-11-876888
Gerds AT, Harrison C, Kiladjian JJ, Mesa R, Vannucchi AM, Komrokji R, et al. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis. Blood Adv [Internet]. 2024 Sep 10 [cited 2025 Jan 10];8(17):4511–22. Available from: https://pubmed.ncbi.nlm.nih.gov/38820422/ DOI: https://doi.org/10.1182/bloodadvances.2024012939
Gupta V, Harrison C, Hexner EO, Al-Ali HK, Foltz L, Montgomery M, et al. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica [Internet]. 2016 Dec 1 [cited 2025 Jan 10];101(12):e482–4. Available from: https://haematologica.org/article/view/7922 DOI: https://doi.org/10.3324/haematol.2016.151449
Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian JJ, Cervantes F, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol [Internet]. 2017 Sep 29 [cited 2025 Jan 10];10(1). Available from: https://pubmed.ncbi.nlm.nih.gov/28962635/ DOI: https://doi.org/10.1186/s13045-017-0527-7
Verstovsek SMD, Richard S. Levy MD, John V. Catalano MD, Richard T. Silver MD, Jimmie H. Harvey Jr, Roger M. Lyons MD, et al. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. 2012;
Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med [Internet]. 2012 Mar [cited 2025 Jan 23];366(9):787–98. Available from: https://pubmed.ncbi.nlm.nih.gov/22375970/
Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med [Internet]. 2012 Mar [cited 2025 Jan 23];366(9):787–98. Available from: https://pubmed.ncbi.nlm.nih.gov/22375970/ DOI: https://doi.org/10.1056/NEJMoa1110556
Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, et al. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol [Internet]. 2015 Aug 1 [cited 2025 Jan 10];1(5):643–51. Available from: https://pubmed.ncbi.nlm.nih.gov/26181658/ DOI: https://doi.org/10.1001/jamaoncol.2015.1590
Cervantes F, Ross DM, Radinoff A, Palandri F, Myasnikov A, Vannucchi AM, et al. Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. Leukemia [Internet]. 2021 Dec 1 [cited 2025 Jan 10];35(12):3455–65. Available from: https://pubmed.ncbi.nlm.nih.gov/34017073/ DOI: https://doi.org/10.1038/s41375-021-01261-x
Maffioli M, Mora B, Ball S, Iurlo A, Elli EM, Finazzi MC, et al. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood Adv [Internet]. 2022 Mar 22 [cited 2025 Jan 10];6(6):1855–64. Available from: https://pubmed.ncbi.nlm.nih.gov/35130339/ DOI: https://doi.org/10.1182/bloodadvances.2021006889
Oh ST, Talpaz M, Gerds AT, Gupta V, Verstovsek S, Mesa R, et al. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv [Internet]. 2020 Sep 1 [cited 2025 Jan 23];4(18):4282–91. Available from: https://pubmed.ncbi.nlm.nih.gov/32915978/ DOI: https://doi.org/10.1182/bloodadvances.2020002662
Mesa RA, Kiladjian JJ, Catalano J V., Devos T, Egyed M, Hellmann A, et al. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis. J Clin Oncol [Internet]. 2017 Dec 1 [cited 2025 Jan 10];35(34):3844–50. Available from: https://pubmed.ncbi.nlm.nih.gov/28930494/ DOI: https://doi.org/10.1200/JCO.2017.73.4418
Gupta V, Oh S, Devos T, Dubruille V, Catalano J, Somervaille TCP, et al. Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial. Leuk Lymphoma [Internet]. 2024 [cited 2025 Jan 10];65(7):965–77. Available from: https://pubmed.ncbi.nlm.nih.gov/38501751/ DOI: https://doi.org/10.1080/10428194.2024.2328800
Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol [Internet]. 2018 Feb 1 [cited 2025 Jan 10];5(2):e73–81. Available from: https://pubmed.ncbi.nlm.nih.gov/29275119/ DOI: https://doi.org/10.1016/S2352-3026(17)30237-5
Harrison CN, Vannucchi AM, Recher C, Passamonti F, Gerds AT, Hernandez-Boluda JC, et al. Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2. Adv Ther. 2024 Sep 1;41(9):3722–35. DOI: https://doi.org/10.1007/s12325-024-02928-4
Verstovsek S, Gerds AT, Vannucchi AM, Vannucchi AM, Al-Ali HK, Lavie D, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet [Internet]. 2023 Jan 28 [cited 2025 Jan 10];401(10373):269–80. Available from: https://pubmed.ncbi.nlm.nih.gov/36709073/
Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, et al. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. J Natl Compr Canc Netw [Internet]. 2017 Oct 1 [cited 2025 Jan 10];15(10):1193–207. Available from: https://pubmed.ncbi.nlm.nih.gov/28982745/ DOI: https://doi.org/10.6004/jnccn.2017.0157
Verstovsek S, Mesa R, Gupta V, Lavie D, Dubruille V, Cambier N, et al. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials. Blood Adv [Internet]. 2023 Jul 25 [cited 2025 Jan 10];7(14):3582–91. Available from: https://pubmed.ncbi.nlm.nih.gov/37042865/ DOI: https://doi.org/10.1182/bloodadvances.2022009311
Kiladjian JJ, Vannucchi AM, Gerds AT, Gupta V, Verstovsek S, Egyed M, et al. Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials. Hemasphere [Internet]. 2023 Nov 27 [cited 2025 Jan 23];7(11):E963. Available from: https://pubmed.ncbi.nlm.nih.gov/37908862/ DOI: https://doi.org/10.1097/HS9.0000000000000963
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Canadian Hematology Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
